Clearmind Medicine (CMND) Q3 2024 earnings summary

Executive summary

• Engaged in phase I/IIa clinical trials for novel psychedelic medicines targeting mental health disorders, with a focus on Alcohol Use Disorder (AUD).

• Completed a Type A FDA meeting and received IND clearance for CMND-100, enabling a Phase I/IIa trial in the US.

• Advanced MEAI-based alcohol substitute beverage program, securing patents and strategic manufacturing partnerships.

• Signed multiple exclusive licensing agreements for addiction and mental health treatments, including PTSD and cocaine addiction.

Financial highlights

• Net loss for the three months ended July 31, 2024, was $2.09 million, compared to $0.58 million in the same quarter last year.

• Net loss for the nine months ended July 31, 2024, was $4.37 million, down from $4.55 million year-over-year.

• Cash and cash equivalents as of July 31, 2024, were $7.68 million, up from $5.43 million as of October 31, 2023.

• Working capital increased to $3.32 million from $0.82 million as of October 31, 2023.

• No revenues generated during the reporting periods.

Outlook and guidance

• Cash position expected to provide sufficient liquidity for at least twelve months, but future capital requirements may exceed current resources.

• Dependent on additional financing to advance clinical programs and potential commercialization.